Inhaled Drug Delivery

This annual conference will include case studies, regulatory updates, latest therapies and technology innovations in two information packed days

1-2 Nov 2018

GBP 1,499
EUR 2,099
USD 2,338

Book now

Conference Overview

This annual conference includes presentations on each of the four principal technologies of inhaled drug delivery – dry powder inhalers, metered dose inhalers, nebulizers and liquid inhalers. It will also cover the future European and UK regulatory processes following Brexit, which will be critical when developing product approval strategies in the future.

There are a number of key areas that are currently evolving and the latest thinking and progress on these will also be presented, including Human factor design and sensing/connecting technologies. These key evolving areas are subject to much debate and require careful consideration whilst developing an inhaled drug product.

Please note that this programme relates to the 2017 event. The new programme and brochure will be available shortly.

Please revisit this page in a few weeks time to see the programme for 2018.

Exhibiton logo *Exhibition stands are available at this meeting, for further information please click here*   *Exhibitor* *Our media partner*

Programme Day One

09.30 Chairman’s welcome and Introduction

Dr Steve Nichols, Director, OINDP Consultancy, UK

09.40 Future needs for inhaled drug delivery

  • What are unmet needs and drivers for change in inhaled delivery systems?
  • How do the delivery systems in common use stack up against unmet needs and change drivers?
  • What are some alternative approaches one might take to enhance a delivery system or develop a new delivery system?

Dr Paul Johnson, Senior Director of Inhaled Product Platforms, GSK, UK

10.20 Innovation in nebulized therapy

  • Nebulized therapy is growing faster than other inhaled dosage forms, albeit from a smaller base
  • There are significant unmet medical needs for patients that would benefit from nebulised therapy, which will be reviewed
  • There are potential commercial advantages to develop nebulized therapies ahead of the corresponding inhaler
  • The use of electronics facilitates the introduction of patient management solutions

Dr John Pritchard, Director PMO and Technology, Respiratory Drug Delivery, Sleep & Respiratory Care, Philips Healthcare, UK

11.00 Discussion

11.10 Refreshments

11.30 Nebulizers – modern advances
Jason Cheng, CEO and Founder, HCmed Innovations

  • New vibrating mesh technology
  • Deepro HCM-860

Irene Wu, Operations Director, HCMed Innovations, The Netherlands

12.10 Functional respiratory imaging: how does it help to optimise drug delivery in the lung

  • What is Functional Respiratory Imaging (FRI)
  • Relation of FRI to APSD methods and scintigraphy
  • FRI as a translational tool
  • Examples

Dr Wim Vos, Co-Founder, FLUIDDA, Belgium

12.50 Discussion

13.00 Lunch

14.10 Developing triple combination inhalers – the challenges

Francesca Usberti, Head of Respiratory Technical Leadership, CMC R&D, Chiesi, UK

14.50 Development of propellant free MDIs

  • AeroMist non pressurized metered dose inhaler
  • Human factors considerations for a new technology in an existing look and feel

Wilbur de Kruijf, Business Development, Medspray, Netherlands

15.30 Discussion

15.40 Refreshments

16.10 The ADI – low velocity aqueous spray device

  • Patient perspective

Tomas Norling, Director Inhalation R&D, Xellia Pharmaceuticals ApS, Denmark

16.50 The feasibility of aerosol-mediated delivery of next generation drugs: vaccines and cell-based therapies

  • Overview of next generation drugs
  • Rationale for pulmonary targeting of vaccines
  • Review of existing vaccine/device combinations
  • Requirements for optimal vaccine delivery
  • Rationale for cell therapy targeted to the lung
  • Review of existing cell therapy/device combinations
  • Requirements for optimal cell therapy delivery
  • Summary and Q&A

Dr Ronan MacLoughlin, Head of Science, Aerogen, Ireland

17.30 Discussion

17.45 End of day one

17.45-18.45 NETWORKING DRINKS

Programme Day Two

09.15 Review of day one

Mike Holroyd, Senior Director, Mylan, UK

09.30 The UK regulatory future – the way forward after Brexit

  • What are the key issues for the pharmaceutical industry for UK and EU 27
  • What have we learnt so far and what are the next stages of the negotiations
  • Preparations for March 2019
  • What should we expect from March 2019

Dr David Jefferys, Senior Vice President, Global Regulatory, Eisai Europe, UK

10.10 Human factor regulations

  • Human factors studies – a hype or a real need?
  • Which guidelines cover human factors for pharmaceutical products? What do the guidelines say?
  • Questions and problems

Dr Stefan Leiner, CMC Expert, Quality and Records Management, Boehringer Ingelheim Pharma GmbH and Co. KGm, Germany

10.50 Discussion

11.00 Refreshments

11.30 How the demands of engineered particles are impacting filling technology…

  • The trend towards engineered particles, including spray-dried powders, is changing the game with regard to development, clinical manufacturing and industrialisation of new formulations and devices
  • We explore the key challenges and what they mean for lab, clinical and commercial manufacturing

Alex Jezequel, Projects Director, 3P Innovation, UK

12.10 Connected Asthma

  • Connected drug delivery devices are here now, and will be a part of the future, but they are not a panacea
  • This presentation will cover important questions such as: which disease indications, patient groups and devices are they appropriate for?
  • How does connectivity affect device development?
  • Who pays and who owns the data?
  • How effective can we expect connectivity to be?

Tom Oakley, Director of Drug Delivery Device Development, Springboard

12.50 Discussion

13.00 Lunch

14.10 MDIs getting connected – Inspair sensor converts any device into a connected device

  • The proper use of the device is one of the major issues in the respiratory field, specifically for PMDIs
  • Inspair, a smart sensor compatible with all PMDIs, can record critical information: the pressure on the canister and the inhalation
  • Inspair is a treatment monitoring solution designed to help patients follow the instructions for use of the device, educate them on the importance of the inhalation technique, and guarantee medication is properly delivered
  • Highly customisable solution, can even be adapted for some DPIs
  • Easy to industrialise for pharma, easy to adopt for patients

Arnaud Guillet, Business Development, Biocorp, France

14.50 *Smart inhalers – Improving adherence and reducing healthcare costs

  • Global health data confirms that poor patient adherence to long-term therapies, such as asthma and COPD, contribute significantly to rising healthcare cost
  • Smart Inhalers are emerging which enable more effective monitory of patient compliance and adherence, including remotely
  • Clinical studies using smart devices have demonstrated improvements and translate directly to a reduction in healthcare cost
  • Smart Inhalers face numerous challenges, from a wide range of stakeholder, for successful adoption on a global scale

Dana Shears, Director, Future Market Development, H&T Presspart, USA

15.30 3M Intelligent Control Inhaler

Sam Van Alstyne, New Products Marketing Manager, 3M Drug Delivery, USA

16.10 Discussion

16.20 Chairmen’s closing remarks

16.30 End of conference and refreshments

Presenters

Stephen Eason

Stephen is an independent consultant with a successful record in innovation and the development of technologies and teams. He founded Vectura Delivery Devices in 2002 and was a member of Vectura’s Executive Leadership Team until 2016 with responsibility for technology and IP. He led the invention and development of the core device technology used in a range of inhalers including GyroHaler®, now approved and marketed in over 30 countries as Sandoz’s AirFluSal® Forspiro®.

From 1987 to 2002 Stephen worked for Cambridge Consultants Limited (CCL). Whilst at CCL he set up and led CCL’s Drug Delivery Devices Group, which carried out significant product developments in the areas of inhalation, injection and infusion products. Before specialising in drug delivery, Stephen managed a number of healthcare, telecoms and consumer product developments for clients in Europe and the US. Prior to joining CCL Stephen worked in design and development for Baxter Healthcare. He studied Mechanical Engineering at Imperial College.

David Jefferys

Dr David Jefferys is currently Senior Vice President with Eisai responsible for Global Regulatory, Government Relations, Public Affairs and Patient Safety (EMEA, Russia and Australasia). After qualifying in medicine he worked in clinical and academic medicine, before spending 20 years as a senior regulator for both medicines and medical devices. He was executive director of the UK Medicines Control Agency, CEO and Director of the MDA, joint CEO of MHRA. He was involved in the establishment of the European Medicines Agency, CPMP/CHMP member and MRFG and PER scheme chairman. For the last ten years he has worked in industry and chairs several key committees for ABPI, Efpia and IFPMA. He has lectured and published extensively in drug and device regulation and on benefit risk evaluation.

Mike Holroyd

Mike Holroyd is Senior Director with responsibility for the design, development and scale-up of inhalation devices within the Mylan Global Respiratory Group. He has an MA in Engineering from St. Catharine’s College, Cambridge. He started his career at Rolls-Royce Aero engines, before moving to PA consulting group where he was a Partner and manager of the product development group. He then joined Norton Healthcare in 1993, where he directed all inhalation device development, including engineering, formulation development and analytical laboratory services and the subcontract manufacture of devices. At Norton he developed, scaled-up and launched Easi-Breathe as well as developing the Spiromax MDPI. He was awarded the Royal Academy of Engineering MacRobert award for the development of Easi-Breathe.
He left Noton (now part of IVAX) to start his own consultancy business, before joining Phoqus Pharmaceuticals as Vice President Engineering to develop novel drug delivery systems based on electrostatic deposition technology. He then returned to consultancy, operating as Programme Director on a major new respiratory device development, until he joined Myland in 2013.

James Tibbatts

Since April 2007 James has been working as an independent consultant specialising in Computational Fluid Dynamics (CFD) analysis for pharmaceutical applications.

James’ academic background was originally in Aeronautical Engineering where he specialised in external aerodynamics with a particular focus on Formula 1 cars. Working as a CFD applications engineer for Fluent UK (which later became ANSYS) James transferred his focus from aerospace and automotive applications towards Chemical Process and latterly Pharmaceutical applications. Since 2005 James has focused entirely on CFD applications for the pharmaceutical industry. During this time most of his work has been on the assessment of fluidisation and deaggrgeation within DPIs.

Mark Copley

Mark Copley graduated from the University of Bath, UK in 2000 with a Masters Degree in Aerospace Engineering. For 8 years he was Technical Sales Manager and product specialist for Copley Scientific’s range of inhaler testing equipment, before coming the Sales Director in 2009. He is now Chief Executive Officer for the company. Mark is considered a leading authority in testing methods and systems for metered-dose inhalers, dry powder inhalers, nebulisers and nasal sprays; authoring and contributing to more than 50 published articles. He also provides application support and consultancy, runs focused training workshops for the inhaled drug testing sector of the pharmaceutical industry and sits on the editorial advisory panel of Inhalation Magazine. An invited member of the European Pharmaceutical Aerosol Group (EPAG) impactor sub-team, Mark has also made recommendations to the Inhalanda working group, leading to subsequent revisions to Ph. Eur. and USP monographs. As part of Copley Scientific’s associate membership of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), Mark participates in a number of working groups with a view to enhancing the regulatory science of orally inhaled and nasal drug products (OINDPs).

Specialties: Methods for the determination of delivered-dose uniformity and aerodynamic particle size distributions of OINDPs.

Regina Scherließ

Prof. Dr. Regina Scherließ (*1979) is a professor for Pharmaceutics and Biopharmaceutics, director of the section Pharmacy and chair of the Department of Pharmaceutics at Kiel University, Germany. As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015). Her research interests include disperse systems and nanoparticles, stabilization of biomolecules in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery.

Anselm Ebert

Dr Anselm Ebert is Global Business Developer at Presspart.
Studies of Molecular Biology and Neuroscience at the Universities of Würzburg (Germany), Hamburg (Germany), Rutgers (New Jersey, US) and Edinburgh (Scotland)
PhD in Neuroscience at Edinburgh University
Work experience:
2009-2011: Senior Business Consultant at FMC Consultancy, spezialized on strategy and restructuring
2012-2015: Director Product Development at Hartmann AG, spezialized on medical products
2016-current: Global Business Developer at Presspart

Arcadia Woods

Dr Arcadia Woods is a holder of the CW Maplethorpe Postdoctoral Research Fellowship in the School of Cancer and Pharmaceutical Sciences, King’s College London. She graduated with BSc Hons in Chemistry from the University of Edinburgh in 2010 and completed her PhD in Pharmaceutical Science at King’s College London in 2015, supervised by Professor Ben Forbes. Arcadia’s research interests lie in developing advanced in vitro systems to understand the fate of biopharmaceutical therapeutics and drug carriers in the lung, and investigating the ability of biocompatible drug carriers to enhance inhaled drug delivery.

George Bostock

George holds a first class Master’s degree in Aeronautical Engineering from Imperial College London. He is also a Chartered Engineer and a Member of the Royal Aeronautical Society. At CDP he works as a Mechanical Engineer, with a particular interest in fluid dynamics. He has gained experience across a wide range of projects, from consumer goods through to medical devices, including a number of performance-critical drug delivery devices within the pharma industry. He was also a named Red-Dot design award winner for CDP’s “First Response Monitor” (FRM).

George enjoys the creative and collaborative aspects of his role at CDP. He is interested in how his previous experiences in Systems Engineering and Robust Design can be leveraged to improve both project and product success. He is also part of the CDP Quality Team, ensuring that projects are run to ISO 9001 and 13485 standards.

Richard Costello

Graduated in Medicine from the RCSI Dublin and then trained on the Pulmonary and Critical Care Fellowship program at The Johns Hopkins Hospital, Baltimore, USA. Following this, he was appointed Senior Lecturer in Professor Peter Calverely’s Department at the University of Liverpool. He moved back to RCSI Dublin in 2000 as a Consultant Physician and Senior Lecturer and has since been promoted through the academic ranks.

Professionally, he is active as a clinician and teacher in both in-patient and out-patient general respiratory and internal medicine. He leads specialist clinics in severe asthma and he is the clinical lead for the National Severe Asthma program and a board member of two severe asthma registries. He leads specialist sleep and ventilation clinics and is Past President of the Irish Sleep Society.

Educationally, he has served as National Specialist Director of Training in Ireland in Respiratory Medicine from 2002-2012, where he developed a structured training program, a curriculum and assessment process. He now leads a research group in Medical Education Department at the Royal College of Physicians of Ireland. He is President of the European Board of Pulmonology, a Board Member of the ERS HERMES respiratory exam group, a Board Member of the ERS Education council and a Board Member of the Asthma Society.

Academically, he is a Health Research Board of Ireland Clinician Scientist. In the last 10 years, he has led a multi-disciplinary group of academics studying how technology can be used to optimise adherence to therapy and improve outcomes in patients with respiratory disease. He has developed, and copyrighted technology related to the assessment of inhaler adherence. He holds several patents related to the use of digital technology. He has published over 120, original research papers in respiratory medicine and has a h-index of 34. His work is currently supported by grants of over €3 million from industry partners and the Health Research Board of Ireland.      

Bo Olsson

Senior Inhalation Consultant
Dr. Olsson has more than 25 years of experience of inhaled formulations having spent equal time on CMC and clinical pharmacology. His specialty is IVIVC with particular emphasis on predicting in vivo outcomes, such as lung deposition, from in vitro data.

Book now

1-2 Nov 2018
1-2 Nov 2018 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • 3P Innovation Ltd
  • Bayer AG
  • Bayer Pharma AG
  • Bering (Nanjing) Scientific Information Ltd
  • Cambridge Design Partnership
  • EVA Pharma
  • Exco InTouch Ltd
  • Fluidda
  • Genetic SpA
  • GlaxoSmithKline Research & Development Ltd
  • H12 Consulting, UK
  • MHRA
  • Novartis Pharma AG
  • Novartis Pharmaceuticals UK Ltd
  • Pfizer Ltd
  • PH&T SpA
  • Respironics Respiratory Drug Delivery (UK) Ltd
  • Rexam Pharma GmbH
  • Roche Diagnostics GmbH
  • Sandoz Limited
  • Schunk Carbon Technology
  • Sepracor Inc
  • SGS Institut Fresenius GmbH
  • Siegfried Pharma Development GmbH
  • TECH GROUP
  • Tech Group Europe
  • Technology Partnership Plc
  • Teva Pharamceuticals
  • Tokyo University of Science
  • Zambon SpA

Very engaging. good number of speakers

Kevin Chilvers, Senior Quality Engineer, Bespak Europe Ltd

Generally really satisfied on terms of the content and speakers as well as the location.

Thierry Rousselot, Clinical Project Manager, Chiesi SAS

Very impressed with all speakers

Peter Davies, Quality Engineer, Bespak Europe Ltd

Very good

James Arnold, Assistant Editor, OnDrugDelivery Ltd

Excellent content, valuable and knowledgable speakers. Liked it. Good.

Aravind Rambhau Sonawane, Manager, Business Development, Sunpharma Global

Its a good mix of topics

Sunita Sule, Inhalator Products Consultant,

Very good conference with plenty of time for networking and high level talks. I will recommend it to my colleagues.

Segolene Sarrailh, Lab Manager, Inhalation & new products, Aptar France

Very worthwhile. Some good and valuable information.

Annmarie Gambrill, Device Analytical Scientist , Mylan Pharma UK Ltd

Networking!

Elena Pasini, Scientist, Chiesi Farmaceutici S.p.A